Long-term health effects of exposure to sarin and other anticholinesterase chemical warfare agents

Military Medicine

Volumn 168, Issue 3, 2003, Pages 239-245

  Page, William F ^a  

^a Institute of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; SARIN;

ADULT; ARTICLE; CAUSE OF DEATH; CHEMICAL WARFARE; CONTROLLED STUDY; HEALTH HAZARD; HUMAN; MAJOR CLINICAL STUDY; OCCUPATIONAL EXPOSURE; RISK ASSESSMENT; SELF REPORT;

EID: 0037340736     PISSN: 00264075     EISSN: None     Source Type: Journal    
DOI: 10.1093/milmed/168.3.239     Document Type: Article

References (16)

1. Committee on Toxicology. Board on Toxicology and Environmental Health Hazards, Possible Long-Term Health Effects of Short-Term Exposure to Chemical Agents, Vol 3: Final Report: Current Health Status of Test Subjects. Washington, DC. National Academy Press, 1985.
2. Special Assistant for Gulf War Illnesses, Department of Defense, US Demolition Operations at Khamisiyah [Case Narrative). Available at http://www.gulflink. osd.mil/khamisiyah_ii/;accessed December 7, 2000.
3. Morita H, Yanagisawa N, Nakajima T, Shimizu M, Hirabayashi H, Okudera H, et al: Sarin poisoning in Matsumoto. Lancet 1995; 346: 290-3.
4. Nozaki H, Aikawa N, Shinozawa Y, Hori S, Fujishima S, Takuma K, Sagoh M: Sarin poisoning in Tokyo subway. Lancet 1995; 345: 980-1.
5. Spencer PS, Wilson BW, Albuquerque EX: "Sarin," "nerve agents," and their antidotes." In: Experimental and Clinical Neurotoxicology, Ed 2, pp 1073-93. Edited by Spencer PS, Schaumburg HH. New York, Oxford University Press, 2000.
6. Page WF, Mahan CM, Kang HK: Vital status ascertainment through the files of the Department of Veterans Affairs and the Social Security Administration. Ann Epidemiol 1996; 6: 102-9.
7. O'Donnell WE, DeSoto CB, DeSoto JL: Validity and reliability of the revised Neuropsychological Impairment Scale (NIS). J Clin Psychol 1993; 49: 372-82.
8. Dyck PJ, Karnes J, O'Brien PC, Swanson CJ: Neuropathy symptom profile in health, motor neuron disease, diabetic neuropathy, and amyloidosis. Neurology 1986; 36: 1300-8.
9. Spitzer RL, Williams JBW: User's Guide for the Structured Clinical Interview for DSM-III revised. Washington, DC, American Psychiatric Press, 1990.
10. Kellner R, Abbott P, Pathak D, Winslow WW, Umland BE: Hostility, somatic symptoms, and hypochondriacal fear and beliefs. J Nerv Mental Dis 1985; 173: 554-60.
11. National Center for Health Statistics: Current Estimates from the National Health Interview Survey, United States, 1993, Vital and Health Statistics. Series 10, No. 190. Washington, DC, U.S, Government Printing Office, 1994.
12. Committee on Toxicology, Board on Toxicology and Environmental Health Hazards: Possible Long-Term Health Effects of Short-Term Exposure to Chemical Agents, Vol 2: Cholinesterase Reactivators. Psychochemicals, and Irritants and Vesicants. Washington, DC, National Academy Press, 1984.
13. Committee on Toxicology, Board on Toxicology and Environmental Health Hazards: Possible Long-Term Health Effects of Short-Term Exposure to Chemical Agents, Vol 1: Anticholinesterases and Anticholinergics. Washington, DC, National Academy Press, 1982.
14. Clinical Research Department: Volunteer screening and selection, SOP No. 5, August 1968, p 12.
15. SAS Institute Inc., SAS/STAT User's Guide, Version 8.0. Cary. NC, SAS Institute Inc., 1999.
16. National Center for Health Statistics: Current Estimates from the National Health Interview Survey, United States, 1996, Vital and Health Statistics, Series 10, No. 200. Washington, DC, U.S. Government Printing Office, 1999.